Back to search results
NCT07569718

Effects of Adolescent Synaptic Pruning

Enrolling by Invitation
NAAges 18+InterventionalBasic science
Beatriz Luna
~60 participants
Updated 2026-05-06 on ClinicalTrials.gov
What's tested:PET Imaging Scan using [11C]UCB-J

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Non-invasive quantification of synaptic pruning
Measured over The PET-CT scan will be within approximately 30 days of the parent study MRI.
+1 more outcome measured

Conditions

Healthy Adult Participants
Synaptic Plasticity

Explore related trials

Healthy Volunteers

NCT07569718

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Laboratory of Neurocognitive Development

    Pittsburgh, Pennsylvaniano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Beatriz Luna, PhD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Males or females between 18-26 years of age, AND currently enrolled in the Parent Project (R01MH067924)

Exclusion

Head injury with loss of consciousness over an hour.
A vision problem or eye movement problem (such as lazy eye, double vision, blurred vision, or color blindness).
A learning disability and/or ever had an Individualized Education Plan (IEP) in school.
Significant neurological or metabolic illness: Epilepsy, Meningitis, Encephalitis, Diabetes, Huntington's disease.
Diagnosed with a psychiatric disorder.
Participants with, or with a first degree relative, having a DSM IV Axis l psychiatricdisorder.
Metal implants or ferromagnetic objects contained within the body which may interfere with the MRI scan (but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant.) Dental fillings do not present a risk for MRI. If there is a possibility of metal being present in the participant's body, the participant will be excluded from the study.
Weight more than 250 pounds.
Claustrophobia or uncomfortable in small spaces.
\<70% on the Achenbach scale (either from Youth Self Report (YSR) or Adult Self Report (ASR)).
IQ \< 80 or IQ \> 130.
Pregnancy or lactation, lack of effective birth control during 15 days before the scans.
Currently employed as radiation worker; or participation in radioactive drug research protocols within the previous year such that the total cumulative annual radiation dose (i.e., from participation in the previous radioactive drug study \[studies\] and this study) would exceed the radiation dose limits specified in the FDA regulations (i.e., 21 CFR 361.1) that govern the research use of \[C-11\]UCB-J
History of drug or alcohol abuse (from parent study eligibility).

What this trial measures

  • Non-invasive quantification of synaptic pruningThe PET-CT scan will be within approximately 30 days of the parent study MRI.

    1\. Age-related changes in synaptic density through young adulthood o Cross-sectional age-related (18-26 years of age) changes in synaptic density via SUVR quantified within the dorsolateral prefrontal cortex.

  • Non-invasive quantification of synaptic pruningThe PET-CT scan will be within approximately 30 days of the parent study MRI.

    2\. Within-subject associations of synapse density to MRI-derived measures of brain membrane byproducts o Synaptic density, based on SUVR modeling of \[11C\]UCB-J acquisitions, will be compared to ultra-high field (7 Tesla) \[31P\]MRSI measurement of membrane phospholipid levels obtained from the same participants.